Nitric oxide-mediated regulation of β -amyloid clearance via alterations of MMP-9/TIMP-1

Journal of Neurochemistry

Volumn 123, Issue 5, 2012, Pages 736-749

  Ridnour, Lisa A ^a   Dhanapal, Sneha ^a   Hoos, Michael ^b   Wilson, Joan ^b   Lee, Jennifer ^b   Cheng, Robert Y S ^a   Brueggemann, Ernst E ^c   Hines, Harry B ^c   Wilcock, Donna M ^b,d   Vitek, Michael P ^b   Wink, David A ^a   Colton, Carol A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USAMRID   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

amyloid; immunity; matrix metalloproteinase 9 (MMP 9); microglia; nitric oxide (NOS2); tissue inhibitor of metalloproteinase 1 (TIMP 1)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; NITRIC OXIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

MUS;

EID: 84868650296     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12028     Document Type: Article

References (67)

1. Aizenstein H. J., Nebes R. D., Saxton J. A., et al,. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509-1517.
2. Backstrom J. R., Lim G. P., Cullen M. J., and, Tokes Z. A., (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16, 7910-7919.
3. Basak J. M., Kim J., Pyatkivskyy Y., Wildsmith K. R., Jiang H., Parsadanian M., Patterson B. W., Bateman R. J., and, Holtzman D. M., (2012) Measurement of apolipoprotein E and amyloid beta clearance rates in the mouse brain using bolus stable isotope labeling. Mol. Neurodegener. 7, 14.
4. Bell R. D., Winkler E. A., Singh I., et al,. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516.
5. Bove P. F., Wesley U. V., Greul A. K., Hristova M., Dostmann W. R., and, van der Vliet A., (2007) Nitric oxide promotes airway epithelial wound repair through enhanced activation of MMP-9. Am. J. Respir. Cell Mol. Biol. 36, 138-146.
6. Candelario-Jalil E., Yang Y., and, Rosenberg G. A., (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994.
7. Colton C. A., and, Wilcock D. M., (2010) Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9, 174-191.
8. Colton C. A., Keri J. E., Chen W. T., and, Monsky W. L., (1993) Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J. Neurosci. Res. 35, 297-304.
9. Colton C., Wilt S., Gilbert D., Chernyshev O., Snell J., and, Dubois-Dalcq M., (1996) Species differences in the generation of reactive oxygen species by microglia. Mol. Chem. Neuropathol. 28, 15-20.
10. Crocker S. J., Frausto R. F., Whitton J. L., and, Milner R., (2008) A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. Glia 56, 1187-1198.
11. Davies K. M., Wink D. A., Saavedra J. E., and, Keefer L. K., (2001) Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution. J. Am. Chem. Soc. 123, 5473-5481.
12. Davis J., Xu F., Deane R., Romanov G., Previti M. L., Zeigler K., Zlokovic B. V., and, Van Nostrand W. E., (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 20296-20306.
13. Death A. K., Nakhla S., McGrath K. C., Martell S., Yue D. K., Jessup W., and, Celermajer D. S., (2002) Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J. Am. Coll. Cardiol. 39, 1943-1950.
14. Gandy S., (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Investig. 115, 1121-1129.
15. Ganster R. W., Taylor B. S., Shao L., and, Geller D. A., (2001) Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl Acad. Sci. USA 98, 8638-8643.
16. Gardner J., and, Ghorpade A., (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J. Neurosci. Res. 74, 801-806.
17. George S. J., and, Johnson J. L., (2010) In situ zymography. Methods Mol. Biol. 622, 271-277.
18. Glenner G. G., (1989) The pathobiology of Alzheimer's disease. Annu. Rev. Med. 40, 45-51.
19. Gordon S., and, Taylor P. R., (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964.
20. Gottschall P. E., (1996) Beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. NeuroReport 7, 3077-3080.
21. Gottschall P. E., and, Yu X., (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 64, 1513-1520.
22. Gottschall P. E., Yu X., and, Bing B., (1995) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 42, 335-342.
23. Guo Z., Shao L., Zheng L., Du Q., Li P., John B., and, Geller D. A., (2012) miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes. Proc. Natl Acad. Sci. USA 109, 5826-5831.
24. Hartell N. A., and, Suh Y. H., (2000) Peptide fragments of beta-amyloid precursor protein: effects on parallel fiber-Purkinje cell synaptic transmission in rat cerebellum. J. Neurochem. 74, 1112-1121.
25. Hawkes C. A., Hartig W., Kacza J., Schliebs R., Weller R. O., Nicoll J. A., and, Carare R. O., (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 121, 431-443.
26. Huang Y., Potter R., Sigurdson W., et al,. (2012) Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch. Neurol. 69, 51-58.
27. Kang J. E., Lim M. M., Bateman R. J., Lee J. J., Smyth L. P., Cirrito J. R., Fujiki N., Nishino S., and, Holtzman D. M., (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005-1007.
28. Kleiner D. E., and, Stetler-Stevenson W. G., (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218, 325-329.
29. Koronyo-Hamaoui M., Ko M. K., Koronyo Y., et al,. (2009) Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111, 1409-1424.
30. Krishnatry A. S., Fung S. M., Brazeau D. A., Soda D., and, Fung H. L., (2011a) Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats. Nitric Oxide 24, 66-76.
31. Krishnatry A. S., Kamei T., Wang H., Qu J., and, Fung H. L., (2011b) Identification of nitroglycerin-induced cysteine modifications of pro-matrix metalloproteinase-9. Rapid Commun. Mass Spectrom. 25, 2291-2298.
32. Laubach V. E., Foley P. L., Shockey K. S., Tribble C. G., and, Kron I. L., (1998) Protective roles of nitric oxide and testosterone in endotoxemia: evidence from NOS-2-deficient mice. Am. J. Physiol. 275, H2211-2218.
33. LeVine H., 3rd, (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309, 274-284.
34. Liao M. C., and, Van Nostrand W. E., (2010) Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 49, 1127-1136.
35. Liu W., Rosenberg G. A., and, Liu K. J., (2006) AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes. J. Neurosci. Res. 84, 360-369.
36. Livak K. J., and, Schmittgen T. D., (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
37. Ma Q. F., Hu J., Wu W. H., Liu H. D., Du J. T., Fu Y., Wu Y. W., Lei P., Zhao Y. F., and, Li Y. M., (2006) Characterization of copper binding to the peptide amyloid-beta(1-16) associated with Alzheimer's disease. Biopolymers 83, 20-31.
38. Miners J. S., Baig S., Palmer J., Palmer L. E., Kehoe P. G., and, Love S., (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240-252.
39. Miners J. S., Baig S., Tayler H., Kehoe P. G., and, Love S., (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J. Neuropathol. Exp. Neurol. 68, 902-914.
40. Miners J. S., Barua N., Kehoe P. G., Gill S., and, Love S., (2011) Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944-959.
41. Morgan D., (2006) Immunotherapy for Alzheimer's disease. J. Alzheimers Dis. 9, 425-432.
42. Mufson E. J., Binder L., Counts S. E., DeKosky S. T., de Toledo-Morrell L., Ginsberg S. D., Ikonomovic M. D., Perez S. E., and, Scheff S. W., (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 123, 13-30.
43. Van Muiswinkel F. L., Raupp S. F., de Vos N. M., Smits H. A., Verhoef J., Eikelenboom P., and, Nottet H. S., (1999) The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. J. Neuroimmunol. 96, 121-130.
44. Patruno A., Pesce M., Marrone A., Speranza L., Grilli A., De Lutiis M. A., Felaco M., and, Reale M., (2012) Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J. Cell. Physiol. 227, 2767-2774.
45. Qiu W. Q., Ye Z., Kholodenko D., Seubert P., and, Selkoe D. J., (1997) Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272, 6641-6646.
46. Ridnour L. A., Windhausen A. N., Isenberg J. S., Yeung N., Thomas D. D., Vitek M. P., Roberts D. D., and, Wink D. A., (2007) Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc. Natl Acad. Sci. USA 104, 16898-16903.
47. Ridnour L. A., Barasch K. M., Windhausen A. N., et al,. (2012) Nitric Oxide Synthase and Breast Cancer: Role of TIMP-1 in NO-mediated Akt Activation. PLoS One 7, 1-15.
48. Roher A. E., Kasunic T. C., Woods A. S., Cotter R. J., Ball M. J., and, Fridman R., (1994) Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun. 205, 1755-1761.
49. Shin C. Y., Lee W. J., Choi J. W., Choi M. S., Ryu J. R., Oh S. J., Cheong J. H., Choi E. Y., and, Ko K. H., (2007) Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide 16, 425-432.
50. Van den Steen P. E., Dubois B., Nelissen I., Rudd P. M., Dwek R. A., and, Opdenakker G., (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375-536.
51. De Strooper B., (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465-494.
52. Tanzi R. E., Moir R. D., and, Wagner S. L., (2004) Clearance of Alzheimer's abeta peptide: the many roads to perdition. Neuron 43, 605-608.
53. Thomas D. D., Miranda K. M., Espey M. G., et al,. (2002) Guide for the use of nitric oxide (NO) donors as probes of the chemistry of NO and related redox species in biological systems. Methods Enzymol. 359, 84-105.
54. Vellas B., Black R., Thal L. J., Fox N. C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., and, Grundman M., (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144-151.
55. Verdile G., Fuller S., Atwood C. S., Laws S. M., Gandy S. E., and, Martins R. N., (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50, 397-409.
56. Van Vickle G. D., Esh C. L., Daugs I. D., et al,. (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am. J. Pathol. 173, 483-493.
57. Wang H. H., Hsieh H. L., and, Yang C. M., (2011) Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9. J. Cell. Physiol. 226, 2244-2256.
58. Wei L., Gravitt P. E., Song H., Maldonado A. M., and, Ozbun M. A., (2009) Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 69, 4878-4884.
59. Weinberg J. B., Misukonis M. A., Shami P. J., et al,. (1995) Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86, 1184-1195.
60. Weiss J. M., Ridnour L. A., Back T., et al,. (2010) Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 207, 2455-2467.
61. Weller R. O., Subash M., Preston S. D., Mazanti I., and, Carare R. O., (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18, 253-266.
62. Wilcock D. M., Lewis M. R., Van Nostrand W. E., Davis J., Previti M. L., Gharkholonarehe N., Vitek M. P., and, Colton C. A., (2008) Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 28, 1537-1545.
63. Wilcock D. M., Morgan D., Gordon M. N., Taylor T. L., Ridnour L. A., Wink D. A., and, Colton C. A., (2011) Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J. Neuroinflammation 8, 115.
64. Yan P., Hu X., Song H., et al,. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566-24574.
65. Yin K. J., Cirrito J. R., Yan P., et al,. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26, 10939-10948.
66. Zhang J. W., and, Gottschall P. E., (1997) Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J. Neurosci. Methods 76, 15-20.
67. del Zoppo G. J., (2010) The neurovascular unit, matrix proteases, and innate inflammation. Ann. N. Y. Acad. Sci. 1207, 46-49.